Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by
rapid growth and early spread. It is a highly lethal disease that typically is diagnosed at a …

Objective Optimal second-line chemotherapy for patients with relapsed small-cell lung
cancer remains debatable. In addition to topotecan or amrubicin monotherapy, re-challenge …

Abstract Introduction The National Comprehensive Cancer Network guidelines recommend
re-challenge with the first-line treatment for relapsed small cell lung cancer (SCLC) with …

Background Relapsed small cell lung cancer (SCLC) is classified into sensitive or resistant
according to treatment-free interval (TFI) longer or shorter than 60 (criteria 1) or 90 (criteria …

Introduction Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL)
chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited …

In this observational study, we assessed treatment patterns and prognostic factors in
patients with small cell lung cancer (SCLC) in a large state-mandated healthcare …

Platinum-based chemotherapy forms the backbone of treatment for many solid cancers.
However, resistance inevitably develops in those with advanced disease. Platinum …

Methods With research ethics board approval, we performed a retrospective chart review of
all patients with resected nsclc who received adjuvant systemic therapy from January 2002 …

Background Extensive-stage small-cell lung cancer (SCLC) patients who progress after
platinum-based chemotherapy are traditionally categorized as platinum sensitive …

Background Etoposide-/platinum-based chemotherapy is the standard first-line treatment for
extensive-disease small cell lung cancer (SCLC), but responses are short-lived and …